丸美生物：向港交所递表 全面提升综合竞争力

Core Viewpoint - Marubi Biotechnology (丸美生物) is planning to issue H-shares to raise funds aimed at enhancing its core strategies, including strengthening its omni-channel sales system, improving brand value, incubating new brands, enhancing R&D capabilities, optimizing the supply chain, and supplementing working capital, with the goal of improving overall competitiveness [1][2] Group 1: Company Strategy and Financial Plans - The funds raised from the H-share issuance will be used entirely to reinforce the company's core strategies, including building a comprehensive omni-channel sales system and enhancing brand value through diversified marketing activities [1][2] - The company emphasizes that the H-share issuance will not lead to a change in control, with Dr. Sun Huaqing and Wang Xiaopu remaining the actual controllers [2] - Marubi plans to invest in both online and offline direct-to-consumer (DTC) capabilities, expand its R&D team, upgrade R&D facilities, and improve supply chain capabilities [2] Group 2: Market Position and Competitive Advantage - Marubi has established a closed-loop value chain for core raw materials, having developed over 80 proprietary ingredients, with more than 30 achieving large-scale production [2] - The company holds 651 global patent applications and has been granted 265 invention patents, positioning its R&D strength among the top in the domestic beauty industry [3] - Marubi's brand has ranked first in China's eye care market for four consecutive years, while its "Lianhuo" brand ranks third in the domestic foundation market [3] Group 3: Industry Growth and Future Outlook - The anti-aging skincare segment is the fastest-growing sub-sector in China's skincare industry, presenting significant growth opportunities for Marubi [3] - The H-share issuance is viewed as a strategic decision for long-term development, aligning with industry trends and enhancing the company's capital strength and core competitiveness [3]